Clinical trials of targeted toxins

Seminars in Cancer Biology

Volumn 6, Issue 5, 1995, Pages 307-317

  Frankel, Arthur E ^a   Tagge, Edward P ^a   Willingham, Mark C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diphtheria toxin; Fusion toxins; Immunotoxins; Pokeweed antiviral protein; Pseudomonas exotoxin; Ricin; Saporin

Indexed keywords

BACTERIAL TOXIN; DIPHTHERIA TOXIN; EXOTOXIN; HYBRID PROTEIN; IMMUNOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RICIN; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

CLINICAL TRIAL; HUMAN; NEOPLASM; REVIEW;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; CLINICAL TRIALS; DIPHTHERIA TOXIN; EXOTOXINS; HUMANS; IMMUNOTOXINS; NEOPLASMS; RECOMBINANT FUSION PROTEINS; RICIN; VIRULENCE FACTORS;

EID: 0029383662     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1995.0039     Document Type: Article

References (77)

1. Skipper H (1979) Historic milestones in cancer biology: A few that are important to cancer treatment (revisited). Semin Oncol 6:506-514
2. Morrow C, Cowan K (1993) Drug resistance and cancer. Adv Exp Med Biol 330:287-305
3. FitzGerald D (1995) Why toxins? Semin Cancer Biol, in press
4. Hus C, Lin Y, Tung T (1974) Further report on therapeutic effect of abrin and ricin on human cancers. J Form Med Assoc 73:526-542
5. Fodstad O, Kvalheim G, Godal A, Lotsberg J, Aamdal S, Host H, Pihl A (1984) Phase I study of the plant protein ricin. Cancer Res 44:862-865
6. Vitetta E, Fulton R, May R, Till M, Uhr J (1987) Redesigning major positions to create antitumor reagents. Science 238:1098-1104
7. Pastan I, FitzGerald D (1992) Recombinant toxins for cancer treatment. Science 254:1173-1177
8. Choe S, Bennett M, Fujii G, Curmi P, Kantardjieff K, Collier R, Eisenberg D (1992) The crystal structure of diphtheria toxin. Nature 357:216-222
9. Brandhuber B, Allured V, Falbel T, McKay D (1988) Mapping the enzymatic active site of Pseudomonas aeruginosa exotoxin A. Proteins 3:146-154
10. Montfort W, Villafranca J, Monzingo A, Ernst S, Katzin B, Rutenber E, Xuong N, Hamlin R, Robertus J (1987) The three- dimensional structure of ricin at 2.8 Angstroms. J Biol Chem 262:5398-5403
11. Monzingo A, Collins E, Ernst S, Irvin J, Robertus J (1993) The 2.5 Angstrom structure of pokeweed antiviral protein. J Mol Biol 233:705-715
12. Greenfield L, Bjorn M, Horn G, Fong D, Buck G, Collier R, Kaplan D (1983) Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage ß. Proc Natl Acad Sci USA 80:6853-6857
13. Gray G, Smith D, Baldridge J, Harkins R, Vasil M, Chen E, Heneyker H (1984) Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 81:2645-2649
14. Lamb F, Roberts L, Lord J (1985) Nucleotide sequence of cloned cDNA coding for preproricin. Eur J Biochem 148:265-270
15. Benatti L, Saccardo M, Dani M, Nitti G, Sassano M, Lorenzetti R, Lappi D, Soria M (1989) Nucleotide sequence of cDNA coding for saporin-6, a type-1 ribosome-inactivating protein from Saponaria officinalis. Eur J Biochem 183:465-470
16. Spitler L, del Rio M, Khentigan A, Wedel N, Brophy N, Miller L, Harkonen W, Rosendorf L, Lee H, Mischak R, Kawahata R, Stoudemire J, Fradkin L, Bautista E, Scannon P (1987) Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 47:1717-1723
17. Oratz R, Speyer J, Wernz J, Hochster H, Meyers M, Mischak R, Spitler L (1990) Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophos- phamide in the treatment of metastatic malignant melanoma: Results of a phase II trial. J Biol Resp Mod 9:345-354
18. Spitler L, Mishak R, Scannon P (1989) Therapy of metastatic melanoma with Xomazyme Mel, a murine monoclonal anti- body-ricin A chain immunotoxin. Int J Rad Appl Instrum [B] 16:625-627
19. Byers V, Rodvien R, Grant K, Durrant L, Hudson K, Baldwin R, Scannon P (1989) Phase I study of monoclonal antibody ricin A chain immunotoxin XOMAZYME-791 in patients with meta- static colon cancer. Cancer Res 47:6153-6160
20. Hertler A, Schlossman D, Borowitz M, Blythman H, Casellas P, Frankel A (1989) An anti-CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin-monensin. Int J Cancer 43:215-219
21. LeMaistre F, Deisseroth A, Fogel B, Meneghetti C, Ma J, Anderson J, Saria E, Lomen P, Byers V (1990) Phase I trial of H65-RTA in patients with chronic lymphocytic leukemia. Blood 76 suppl 1:295a
22. LeMaistre C, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P, Byers V (1991) Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 76:1173-1182
23. Waldman T, Pastan I, Gansow O, Junghans R (1992) The multichain interleukin-2 receptor: A target for immunotherapy. Ann Intern Med 116:148-160
24. Gould B, Borowitz M, Groves E, Carter P, Anthony D, Weiner J, Frankel A (1989) A phase I study of a continuous infusion anti- breast cancer immunotoxin: Report of a targeted toxicity not predicted by animal studies. JNCI 81:775-781
25. Weiner L, O’Dwyer J, Kitson J, Comis R, Frankel A, Bauer R, Konrad M, Groves E (1989) Phase I evaluation of an anti-breast ca monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 49:4062-4067
26. Pai L, Bookman M, Ozols R, Young R, Smith J, Longo D, Gould B, Frankel A, McClay E, Howell S, Reed E, Willingham M, FitzGerald D, Pastan I (1991) Clinical evaluation of intra- peritoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 9:2095-2103
27. Bookman M, Godfrey S, Padavic K, Griffin T, Corda J, Hamilton T, Ozols R, Groves E (1990) Anti-transferrin receptor immunotoxin (IT) therapy: Phase I intraperitoneal (i.p.) trial. Proc Am Soc Clin Oncol 9:187
28. Laske D, Muraszko K, Oldfield E, DeVroom H, Sung C, Dedrick R, Simon T, Solomon D, Copeland C, Katz D, Groves E, Greenfield L, Houston L, Youle R (1992) Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Proc Third Intl Symp Immunotoxin. Orlando, p 124
29. Soler-Rodriguez A, Ghetie M, Oppenheimer-Marks N, Uhr J, Vitetta E (1993) Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: Implications for vascular leak syndrome. Exp Cell Res 206:227-234
30. Blakey D, Watson G, Knowles P, Thorpe P (1987) Effect of chemical deglycosylation of ricin A-chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A-chain and anti-Thy 1.1 antibody. Cancer Res 47:947-952
31. Amlot P, Stone M, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe P, Uhr J, Vitetta E (1993) A phase I study of an anti-CD22- deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624-2633
32. Vitetta E, Stone M, Amlot P, Fay J, May R, Till M, Newmn J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr J, Thorpe P (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052-4058
33. Grossbard M, Freedman A, Ritz J, Coral F, Goldmacher V, Eliseo L, Spector N, Dear K, Lambert J, Blatter W, Taylor J, Nadler L (1992) Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. Blood 79:576-585
34. Grossbard M, Lambert J, Goldmacher V, Spector N, Kinsella J, Eliseo L, Coral F, Taylor J, Blattler W, Epstein C, Nadler L (1993) Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726-737
35. Uckun F (1995) B43-pokeweed antiviral protein (B43-PAP) immunotoxin. Proc Fourth Intl Symp on Immunotoxins. Myrtle Beach, p 162
36. Falini B, Pasqualucci L, Flenghi L, Bolognesi A, Kadin M, Stein H, Martelli M, Stirpe F (1995) Anti-CD30 immunotoxins: Experimental and clinical studies. Proc Fourth Intl Symp on Immunotoxins. Myrtle Beach, p 160
37. Strom T, Kelley V, Murphy J, Nichols J, Woodworth T (1994) Interleukin-2 receptor-directed therapies: Antibody- or cyto- kine-based targeting molecules. Adv Nephology 23:347-356
38. Foss F, Borkowski T, Gilliom M, Stetler-Stevenson M, Jaffe E, Figg W, Tompkins A, Bastian A, Nylen P, Woodworth T, Udey M, Sausville E (1994) Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 84:1765-1774
39. Foss F, Nichols J, Parker K (1995) Phase I/II trial of DAB389IL- 2 in patients with NHL, HD and CTCL. Proc Fourth Intl Symp on Immunotoxins. Myrtle Beach, p 159
40. Pai L, Wittes R, Setser A, Goldspiel B, FitzGerald D, Willingham M, Pastan I (1995) Phase I and pharmacokinetic study of the immunotoxin LMB-1 (B3-LysPE38). Proc Fourth Intl Symp Immunotoxins. Myrtle Beach, p 163
41. Lynch T, Grossbard M, Fidias P, Bartholomay M, Coral F, Salgia R, Elias A, Skarin A, Sheffner J, Wen P, Arinello P, Bramen G, Esseltine D, Ritz J (1995) Immunotoxin therapy of small cell lung cancer (SCLC): Clinical trials of N901-blocked ricin (N901-bR). Proc Fourth Intl Symp on Immunotoxins. Myrtle Beach, p 164
42. Goldberg M, Heimbrook D, Russo P, Sarosdy M, Greenberg R, Giantonio B, Linehan W, Walther M, Fisher H, Messing E, Crawford E, Oliff A, Pastan I (1995) Clin Cancer Res 1:57-61
43. Laske D, Oldfield E, Youle R (1995) Immunotoxins for brain tumor therapy. Proc Fourth Intl Symp Immunotoxins. Myrtle Beach, p 166
44. Willingham M, Brother T, Tagge D, Frankel A (1995) Endothe- lial apoptosis in immunotoxin-induced vascular leak syndrome: An in vitro model. Modern Path 8:36A
45. Baluna R, Ghetie V, Oppenheimer-Marks N, Vitetta E (1995) The binding of ricin A-chain to fibronectin: Possible implications for vascular leak syndrome in immunotoxin-treated patients. Proc Fourth Intl Symp Immunotoxins. Myrtle Beach, p 144
46. Schnell R, Hatwig M, Radszuhn A, Cebe F, Drillich S, Schon G, Bohlen H, Tesch H, Hansmann M, Schindler J, Ghetie V, Uhr J, Diehl V, Vitetta E, Engert A (1995) A clinical phase I study of an anti-CD25-deglycosylated ricin A-chain immunotoxin (RFT5- SMPT-dgA) in patients with refractory Hodgkin’s disease. Proc Fourth Intl Symp Immunotoxins. Myrtle Beach, p 161
47. Uckun F (1993) Annotation: Immunotoxins for the treatment of leukaemia. Br J Haematol 85:435-438
48. Falini B, Bolognesi A, Flenghi L, Tazzari P, Broe M, Stein H, Durkop H, Aversa F, Corneli P, Pizzolo G, Barbabietola G, Sabattini E, Pileri S, Martelli M, Stirpe F (1992) Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immu- notoxin. Lancet 339:1195-1196
49. Jain R (1994) Barriers to drug delivery in solid tumors. Sci Am 271:58-65
50. Esseltine D, Grossbard M, McLaughlin P, Murray J, Freedman A, Braman G, Nadler L (1995) Anti-B4-blocked ricin (anti- B4-bR) immunotoxin (IT) in the treatment of B-cell lymphoma and leukemia. Proc Fourth Intl Symp on Immunotoxins. Myrtle Beach, p 157
51. Skipper H, Perry S (1970) Kinetics of normal and leukemic leucocyte populations and relevance to chemotherapy. Cancer Res 30:1883-1897
52. Schipper H, Goh C, Wang T (1995) Shifting the cancer paradigm: Must we kill to cure? J Clin Oncol 13:801-807
53. Theodoulou M, Baselga J, Scher H, Dantis L, Trainor K, Mendelsohn J, Howes L, Elledge R, Ravdin P, Bacha P, Brandt- Sarif T, Osborne K (1995) Phase I dose-escalation study of the safety, tolerability, pharmacokinetics and biologic effects of DAB389EGF in patients with solid malignancies that express EGF receptors (EGFr). Proc Am Soc Clin Oncol 14:480
54. Grossbard M, Gribben J, Freedman A, Lambert J, Kinsella J, Rabinowe S, Eliseo L, Taylor J, Blatter W, Epstein C, Nadler L (1993) Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin’s lymphoma. Blood 81:2263-2271
55. Verdonck L, van Putten W, Hagenbeek A, Schouten H, Sonneveld P, van Imhoff G, Kluin-Nelemans H, Raemaekers J, van Oers R, Haak H, Schots R, Dekker A, de Gast G, Lowenberg B (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowing responding patients with aggressive non-Hodgkin’s lymphoma. New England J Med 332:1045-1051
56. Scadden D, Doweiko J, Bernstein Z, Schenkein D, Luskey B, Bresnahan J, Stram D, Esseltine D, Levine A (1995) Combined immunotoxin and chemotherapy for initial treatment of AIDS lymphoma. Proc Fourth Intl Symp Immunotoxins. Myrtle Beach, p 169
57. Bjorn M, Ring D, Frankel A (1985) Evaluation of monoclonal antibodies for the development of breast cancer immunotox- ins. Cancer Res 45:1214-1221
58. Vitetta E, Uhr J (1994) Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy. Cancer Res 54:5301-5309
59. Estis L, Krueger J, Nichols J, Parker K (1995) Psoriasis: A potential target for DAB389IL-2. Proc Fourth Intl Symp Immu- notoxins. Myrtle Beach, p 167
60. Greaves M, Weinstein G (1995) Treatment of psoriasis. New Engl J Med 332:581-588
61. Seki T, Arai Y (1993) Distribution and possible roles of the highly polysialylated neural cell adhesion molecule (NCAM-H) in the developing and adult central nervous system. Neurosci Res 17:265-290
62. Saleh M, LoBuglio A, Sugarman S, Murray J, Onetto N, Warner G, Mezza L, Davidson T, Grizzle W, Daniel C, LeBherz D, Healey D, Baron T, van Leeuwen D, Canetta R, Hellstrom K (1995) Gastrointestinal effects of chimeric BR96-Doxorubicin (DOX) conjugate. Proc Am Assoc Cancer Res 36:483
63. Carpenter G (1987) Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56:881-914
64. Frankel A, Ring D, Tringale F (1985) Tissue distribution of breast cancer associated antigens defined by monoclonal antibodies. J Biol Resp Mod 4:273-286
65. Siegall C, Liggitt D, Chace D, Tepper M, Fell H (1994) Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci USA 91:9514-9518
66. Chace D, Siegall C (1995) Characterization of immunotoxin- induced vascular leak syndrome in rats. Proc Fourth Intl Symp Immunotoxins. Myrtle Beach, p 139
67. Ohnuma T, Kikuchi T, Kohno N, Spitler L, Holland J (1995) Penetration of immunotoxin and cytotoxic agents into multi- cellular spheroids and their cell kill effects. Proc Fourth Intl Symp on Immunotoxins. Myrtle Beach, p 119
68. Sung C, van Osdol W (1995) Effects of molecular weight and intracellular processing on tumor penetration of immunotox- ins. Proc Fourth Intl Symp Immunotoxins. Myrtle Beach, p 118
69. Roscoe D, Jung S, Benhar I, Pai L, Lee B, Pastan I (1994) Primate antibody response to immunotoxin: Serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin. Infect Immun 62:5055-5060
70. Lemley P, Amanatides P, Wright D (1994) Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma 13:417-421
71. Pai L, FitzGerald D, Tepper M, Schachter B, Spitalny G, Pastan I (1990) Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exo- toxin by 15-deoxyspergualin in mice. Cancer Res 50:7750-7760
72. Noon E, Shanahan S, Linsley P, Noelle R, Vitetta E (1995) Reduction in the murine anti-immunotoxin antibody response using novel immunosuppressive agents. Proc Fourth Intl Symp Immunotoxins. Myrtle Beach, p 150
73. Rybak S, Hoogenboom H, Meade H, Youle R (1992) Human- ization of immunotoxins. Proc Natl Acad Sci USA 89:3165-3169
74. Byers V, Henslee P, Kernan N (1990) Use of an anti-pan T-lymphocyte ricin A chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 75:1426-1432
75. Strand V, Lipsky P, Cannon G (1991) Treatment of rheumatoid arthritis with an anti-CD5 immunoconjugate: Final results of phase II studies. Arthritis Rheum 34: S91
76. Woodworth T, Parker K, Sewell K (1992) Pilot studies demonstrating DAB486IL2 (DAB) associated safety and improvement in parameters of disease activity in patients with severe, refractory rheumatoid arthritis (RA) and early autoimmune type I diabetes mellitus (DM). Proc Third Intl Symp on Immunotoxins. Orlando, p 130
77. The IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology 43:655-661